Markets
BSE See NSE See 39,119.83
-332.24 (-0.84%)
collapse Related Readings collapse

Stock Pick From The Pharma Sector

| 4/4/2013 9:00 PM Thursday

HERE IS WHY:

  • Recently launched products in the US markets are doing well
  • DRL is a marquee name and has a consistent dividend payment history
  • The company is increasing its R&D investments, promising more product launches
Defensive sectors are back in demand owing to the underperformance of growth sectors and the overall uncertainty in the markets. While the Sensex clocked a six per cent return last year the BSE Pharma index gained 21 per cent. All the leading stocks in this sector displayed a price appreciation. Realising this, we had earlier recommended Sun Pharma which is doing quite well on the bourses. In this issue, we are recommending another top company from the Pharma sector, Dr Reddy’s Laboratories (DRL).

A number of reasons make DRL a stock worth recommending. First in line is the company’s strong profitable fiscal so far. The products it launched in the US markets this year are enjoying a good market share indicating towards good numbers in FY13 as also in FY14. The company will also continue enjoying benefits of the rupee remaining at the same levels even if it does not depreciate further. Besides, the company has started investing more in research related activities which promises launches in niche segments in the near future. All these factors make a strong case for buying this stock.

DRL has two business segments - Global Generics and Pharma Services and Active Ingredients (PSAI). The Global Generics business is the largest, contributing to 75 per cent of its revenue, while PSAI brings in the rest (25 per cent) of its revenues. DRL has a sound product pipeline and growth strategies in place for both the segments which ensures that the company will not see a slowdown anytime soon.

In the domestic market, DRL is a marquee name with a market share of two per cent. Its top brands such as Omez, Nise and Stamlo are enjoying a leadership position. The company’s four year CAGR of 12 per cent in domestic revenues is lower than the industry average but the company is increasing its sales force, and launching more drugs to increase its domestic business.

Shareholding Pattern as on 31-12-2012
Promoters 55
FII 8.93
DII 1.69
Public 23.39
Bodies Corporate 10.99
GRAND TOTAL 100

DRL has geographically diversified its business and currently derives 83 per cent of its total revenues from exports. Its prominent presence is in the US markets from where it derives 36 per cent of its total revenues. The US business is already showing an improvement in performance, which is likely to continue in the future with its pipeline of 65 products including eight ‘First to File’ drugs. Among the recently launched drugs, DRL enjoys a major market share in some products and has reported a sustained market share in the products in its base business. This should be considered a good sign for its future revenues.

Besides the US markets, Russia is also a very important territory for DRL as it adds 15 per cent to the company’s topline. Except European generics (seven per cent of total revenues), all other markets are showing a good performance and there is thus no sign of worry on the growth front.

On the financial front, from FY08 to FY12, DRL’s revenues have grown at a CAGR of 11 per cent. Profitability has increased at a faster rate with the net profit margins increasing from eight per cent in FY08 to 16 per cent in FY12. For 9MFY13, DRL has reported an 18 per cent growth in its revenues. The net profit remained muted due to a high-base impact caused by the end of the 180-day exclusivity of Generic Zyprexa. This, however, is a one-off event as the company has already launched a few drugs in the US markets and is expecting higher revenues from them.

On the valuation front, at its CMP of Rs 1838, the stock is available at a TTM price to earnings multiple of 22x. We would advise an entry in the stock at its CMP with a price target of Rs 2100 in one year’s time.

Last Five Quarters (Rs/Cr)
Dec '12Sep '12Jun '12Mar '12Dec '11
Total Income 2865.2 2880.85 2540.61 2658.45 2769.2
Operating profit 429.2 484.6 369.89 397.32 738.24
Interest 9.68 -37.1 21.16 -9.37 -19.92
Tax 82.65 156.74 36.5 83.79 261.68
Net Profit 360.18 404.6 334.08 342.7 512.96
Equity Capital 84.92 84.92 84.9 84.78 84.78

 

Find More Articles on: DSIJ Magazine, Choice Scrip, Stock Recommendations, Fundamental Picks, Product, Large Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

Index trend and stocks in action June 17, 2019

Karan DSIJ / Article rating: 5.0

In case Nifty falls below the level of 11,770, it may test the 11,600 mark in the near term. To move upside, the bulls need to move above the 20-DMA once again and sustain for at least two to three days. Only then, the bulls will gain confidence. Stocks in news: BHEL, Elecon Engineering Company, PG Electroplast, FDC, Divi’s Laboratories, Symphony, Coromandel International, Voltas.

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.